Ending diagnostic odysseys and inspiring hope
For patients with rare and complex conditions, physicians and other healthcare professionals need trusted answers. Our tests are developed through leading-edge research and unmatched clinical expertise, creating a diagnostics ecosystem that delivers insights that set a new standard in diagnostic care.
Successful patient outcomes are our priority, and we work with hospitals and physicians around the world to elevate diagnostic excellence everywhere. As part of Mayo Clinic’s healthcare system, we understand the best care is provided locally. We complement local expertise by working with clients and logistics organizations to optimize the specimen journey to our laboratories, enabling physicians to get the results they need and patients to remain at home, focused on healing.
Relentless pursuit of answers
Ongoing research propels test development at Mayo Clinic Laboratories, enabling innovative testing that delivers faster, reliable answers to confidently diagnose patients. Our test results not only equip physicians and patients with meaningful diagnostic, prognostic, and therapeutic insights, they also provide hope for a healthier future.
Experience and expertise you can trust
Mayo Clinic Laboratories’ scientists and physicians are leaders in their fields and able to consult on test selection, utilization, and results interpretation. The exchange of knowledge is a founding principle of Mayo Clinic, and we are committed to sharing lessons we’ve learned with our global collaborators through educational opportunities to help improve care delivery in local practices. This is supported through an expansive library of educational content, podcasts, and stories that showcase breakthroughs in test development and perspectives from Mayo Clinic experts.
Access to groundbreaking diagnostics
Driven by an instinct to innovate, we transform scientific discoveries into meaningful advancements in diagnostic testing. Supported by a robust network of Mayo Clinic physicians and scientists and forward-thinking laboratory partners, we foster access to new and advanced testing, much of which is unavailable elsewhere. This integration connects physicians and hospitals around the world with multiple innovative solutions all in one place to support better patient outcomes.
“We treat all of the specimens we receive with the same high degree of care and quality, regardless of where the sample is coming from. We could be testing a sample from a patient that lives in Rochester, Minnesota, or from someone that lives halfway across the world.”
Bobbi Pritt, M.D., Director of the Clinical Parasitology Laboratory
OUR DIFFERENCE
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Reade Quinton, M.D., assistant professor of Laboratory Medicine and Pathology, to discuss Dr. Quinton’s road to becoming a magician and how to use magic in medicine.
Maria Alice Willrich, Ph.D., explains kappa free light chain testing — Mayo Clinic Laboratories' data-driven approach to diagnose multiple sclerosis. The automated assay is more sensitive, cost-effective, and faster than traditional oligoclonal banding, enabling definitive answers for the challenging diagnosis.
Mayo Clinic researchers have developed and validated a new antibody test to diagnose multiple sclerosis (MS). The new test is an automated and cost-effective method compared to other tests used to diagnose MS, according to the research published in Mayo Clinic Proceedings. The test is now available through Mayo Clinic Laboratories.
Each day, some 40 to 45 thousand specimens are shipped to Mayo Clinic Laboratories in Rochester, Minnesota, from hospitals and other health care organizations around the world. And for every sample, there’s a patient to whom it belongs, someone on the other end hoping for answers to a challenging, perhaps even life-threatening, condition.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Venkatesh Bellamkonda, M.D., assistant professor of Emergency Medicine and the Wellness Officer for the Department of Emergency Medicine at Mayo Clinic, to discuss the importance of wellness and well-being.
John Lieske, M.D., discusses Mayo Clinic Laboratories' urinary ammonium testing. A test that takes the guesswork out of determining acid base disorders by giving nephrologists a true understanding of a patient’s true urinary ammonium level.
This Feature Includes: Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data.
Successful implementation of a new slide scanning and analysis platform across five laboratories represents a significant step forward in Mayo Clinic’s digital pathology program — an initiative that combines advanced technology with human expertise to better serve patients.
A Mayo Clinic Laboratories newborn screening panel detects a rare disease and paves the way for life-sustaining treatment.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Dr. Bill Morice, professor of Laboratory Medicine and Pathology, chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and president of Mayo Clinic Laboratories, to discuss the laboratory’s role in health and equity.
CPT Code updates posted to mayocliniclabs.com during the month of February
Audrey Schuetz, M.D., provides a detailed overview of Mayo Clinic Laboratories’ new culture-based extended spectrum beta lactamase (ESBL) testing. Used to screen for the presence of multi-drug resistant gram-negative bacteria in donor stool intended for fecal microbiota transplantation, the screening test is performed on stool or swab samples taken from around the anus to detect potentially harmful ESBL bacteria that could jeopardize the outcomes of fecal microbiota transplants -- especially in patients who carry the bacteria in their gut without getting sick.